These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34147205)

  • 1. An industrial perspective on co-crystals: Screening, identification and development of the less utilised solid form in drug discovery and development.
    Kendall T; Stratford S; Patterson AR; Lunt RA; Cruickshank D; Bonnaud T; Scott CD
    Prog Med Chem; 2021; 60():345-442. PubMed ID: 34147205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State of the Art of Pharmaceutical Solid Forms: from Crystal Property Issues to Nanocrystals Formulation.
    Couillaud BM; Espeau P; Mignet N; Corvis Y
    ChemMedChem; 2019 Jan; 14(1):8-23. PubMed ID: 30457705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism and crystallization of active pharmaceutical ingredients (APIs).
    Lu J; Rohani S
    Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Insight on Pharmaceutical Co-crystals for Improvement of Aqueous Solubility.
    Malik J; Khatkar A; Nanda A
    Curr Drug Targets; 2023; 24(2):157-170. PubMed ID: 36380409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?
    Braga D; Casali L; Grepioni F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards medicinal mechanochemistry: evolution of milling from pharmaceutical solid form screening to the synthesis of active pharmaceutical ingredients (APIs).
    Tan D; Loots L; Friščić T
    Chem Commun (Camb); 2016 Jun; 52(50):7760-81. PubMed ID: 27185190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of co-crystals in pharmaceutical design.
    Steed JW
    Trends Pharmacol Sci; 2013 Mar; 34(3):185-93. PubMed ID: 23347591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical co-crystals-an opportunity for drug product enhancement.
    Miroshnyk I; Mirza S; Sandler N
    Expert Opin Drug Deliv; 2009 Apr; 6(4):333-41. PubMed ID: 19348603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid State Concerns During Drug Discovery and Development: Thermodynamic and Kinetic Aspects of Crystal Polymorphism and the Special Cases of Concomitant Polymorphs, Co-Crystals and Glasses.
    Otto DP; De Villiers MM
    Curr Drug Discov Technol; 2017; 14(2):72-105. PubMed ID: 27908255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery.
    Al-Obaidi H; Majumder M; Bari F
    Curr Pharm Des; 2017; 23(3):350-361. PubMed ID: 27829335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review.
    Nugrahani I; Jessica MA
    Molecules; 2021 May; 26(11):. PubMed ID: 34071731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polymorph transformation of solid drugs].
    Zhang Q; Mei XF
    Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental cocrystal screening and solution based scale-up cocrystallization methods.
    Malamatari M; Ross SA; Douroumis D; Velaga SP
    Adv Drug Deliv Rev; 2017 Aug; 117():162-177. PubMed ID: 28811184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and Quality Control of Pharmaceutical Cocrystals.
    Izutsu KI; Koide T; Takata N; Ikeda Y; Ono M; Inoue M; Fukami T; Yonemochi E
    Chem Pharm Bull (Tokyo); 2016 Oct; 64(10):1421-1430. PubMed ID: 27319284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Crystalline modifications and polymorphism changes during drug manufacture].
    Doelker E
    Ann Pharm Fr; 2002 May; 60(3):161-76. PubMed ID: 12050595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.